YS Key Statistics, Chart & Performance
The current stock price of YS is 1.02 USD. In the past month the price increased by 27.5%. In the past year, price decreased by -22.73%.
YS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About YS
Company Profile
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 773 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Company Info
YS BIOPHARMA CO LTD
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park
Beijing BEIJING CN
Employees: 773
Phone: 17327133678
YS BIOPHARMA CO LTD / YS FAQ
What does YS do?
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 773 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
What is the current price of YS stock?
The current stock price of YS is 1.02 USD. The price increased by 12.45% in the last trading session.
Does YS BIOPHARMA CO LTD pay dividends?
YS does not pay a dividend.
What is the ChartMill technical and fundamental rating of YS stock?
YS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists YS stock?
YS stock is listed on the Nasdaq exchange.
How is the valuation of YS BIOPHARMA CO LTD (YS) based on its PE ratio?
YS BIOPHARMA CO LTD (YS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.42).
Would investing in YS BIOPHARMA CO LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on YS.
YS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to YS. When comparing the yearly performance of all stocks, YS is one of the better performing stocks in the market, outperforming 96.68% of all stocks.
YS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to YS. YS may be in some trouble as it scores bad on both profitability and health.
YS Financial Highlights
Over the last trailing twelve months YS reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS decreased by -9348.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.59% | ||
| ROE | -50.88% | ||
| Debt/Equity | 0.65 |
YS Forecast & Estimates
9 analysts have analysed YS and the average price target is 4.26 USD. This implies a price increase of 317.5% is expected in the next year compared to the current price of 1.02.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth -6.61% for YS